Schubert & Co’s United Therapeutics UTHR Stock Holding History

Schubert & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32	Closed	-$7.17K	–	1452
2023 Q1	$7.17K	Sell	32 -4	-11%	-$986	0.01%	317
2022 Q4	$10K	Buy	36 +6	+20%	+$1.51K	0.01%	224
2022 Q3	$6K	Sell	30 -1	-3%	-$224	0.01%	365
2022 Q2	$7K	Buy	31 +23	+288%	+$4.68K	0.01%	262
2022 Q1	$1K	Sell	8 -2	-20%	-$381	﹤0.01%	952
2021 Q4	$2K	Buy	+10	New	+$1.96K	﹤0.01%	462

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Schubert & Co's UTHR Position: Q2 2023 in Review

Schubert & Co sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 32 shares — an estimated $7.17K sold.

Schubert & Co first reported a position in UTHR in Q4 2021 and held it in 6 quarters. The position peaked at $10K in Q4 2022. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Schubert & Co reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 32 United Therapeutics shares in Q2 2023, an estimated $7.17K.
Schubert & Co first reported a position in United Therapeutics in Q4 2021 and held it in 6 quarters.
Schubert & Co's United Therapeutics position peaked at $10K in Q4 2022.
473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.